1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,150 | 6,300 | 07:13 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.07. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 68 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 29.07. | Zydus Announces Completion of the Acquisition of an 85.6% Stake in Amplitude Surgical and Upcoming Filing of a Simplified Tender Offer | 308 | Business Wire | Regulatory News:
Zydus Lifesciences Limited1 ("Zydus"), on March 11, 2025, entered into agreements with PAI and two minority shareholders of Amplitude Surgical (Paris:AMPLI) to acquire blocks of... ► Artikel lesen | |
| 29.07. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 144 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 29.07. | Amplitude Surgical - Suspension of Listing | 290 | Business Wire | Regulatory News:
Amplitude Surgical company has requested Euronext to suspend the listing of its shares (ISIN: FR0012789667, Ticker: AMPLI, eligible PEA-PME) on Euronext market with effect as from... ► Artikel lesen | |
| 24.07. | Amplitude Surgical - Consolidated annual revenue of €110.8 million, up +5.7% at constant exchange rates | 240 | Business Wire | Business growth of +3.8% at constant exchange rates in the fourth quarter of the 2024-25 financial year and of +5.7% for the full year
Strong momentum in France: revenue up +4.8%
Solid... ► Artikel lesen | |
| 25.04. | Zydus Lifesciences Limited Signs Purchase Agreement with PAI Partners and Other Shareholders to Acquire a Majority Stake in Amplitude Surgical SA | 372 | Business Wire | Regulatory News:
Amplitude Surgical SA (Paris:AMPLI):
Following the joint announcement of March 11, 2025, Zydus Lifesciences Limited ("Zydus") and Amplitude Surgical SA (Paris:AMPLI) ("Amplitude")... ► Artikel lesen | |
| 17.04. | Amplitude Surgical - 9-Months Consolidated Sales for FY 2024-25 of €83.8m, up +6.4% at Constant Exchange Rates | 299 | Business Wire | Sales up +6.6% at constant exchange rates in Q3 FY 2024-25
Consolidated sales for 9 months up+ 6.4% at constant exchange rates to €83.8m
Good momentum in France: sales up +4.7% over... ► Artikel lesen | |
| 17.04. | Zydus Lifesciences Limited announces the execution of undertakings to tender as part of its envisaged tender offer for Amplitude Surgical SA shares | 286 | PR Newswire | AHMEDABAD, India and PARIS, April 17, 2025 /PRNewswire/ -- Following the announcement of its envisaged tender offer on March 11, 2025, Zydus Lifesciences Limited announces the execution of... ► Artikel lesen | |
| AMPLITUDE SURGICAL Aktie jetzt für 0€ handeln | |||||
| 17.04. | Amplitude Surgical Has Been Informed by Zydus Lifesciences Limited of the Execution of Undertakings to Tender as Part of Its Envisaged Tender Offer for Amplitude Surgical SA Shares | 258 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible).
Following the announcement of the envisaged tender offer on March 11, 2025 of Zydus Lifesciences Limited... ► Artikel lesen | |
| 26.03. | Amplitude Surgical Announces H1 2024-25 Results: 51.5 M€ Sales and 13.1 M€ EBITDA | 388 | Business Wire | Consolidated sales of €51.5m, up 6.3% at constant exchange rates
EBITDA up 10.6% to €13.1 million, EBITDA margin 25.4%
Current operating income of €6.0 million
Cash position... ► Artikel lesen | |
| 12.03. | XFRA 1AU: WIEDERAUFNAHME/RESUMPTION | 219 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.03. | XFRA 1AU: AUSSETZUNG/SUSPENSION | 229 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAMPLITUDE SURGIC.... ► Artikel lesen | |
| 11.03. | Zydus Life inks pact to acquire majority stake in Amplitude Surgical | 2 | capitalmarket.com | ||
| 11.03. | Zydus Enters Exclusive Negotiations with PAI Partners and Other Shareholders to Acquire a Majority stake in Amplitude Surgical, France | 394 | Business Wire | Completion of the transaction to be followed by mandatory simplified tender offer
Zydus has entered into exclusive negotiations to acquire a controlling shareholding in Amplitude Surgical,... ► Artikel lesen | |
| 20.02. | Amplitude Surgical - 1st Half-year 2024-25: Consolidated Sales of €51.5m, +6.3% at Constant Exchange Rates | 330 | Business Wire | Consolidated sales of €51.5 million, up+ 6.3% at constant exchange rates
Good sales growth in France at +4.6%
Strong growth in international business thanks to subsidiaries, with... ► Artikel lesen | |
| 21.11.24 | Amplitude Surgical - First Quarter 2024-25: Consolidated Sales of €21.8m, +7.5% at Constant Exchange Rates | 586 | Business Wire | VALENCE, France--(BUSINESS WIRE)--Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics... ► Artikel lesen | |
| 20.11.24 | Amplitude Surgical Announces Its 2024-25 Financial Calendar | 130 | Business Wire | Regulatory News:
Amplitude Surgical (ISIN: FR0012789667, Mnemo: AMPLI, PEA-PME eligible), the French market leader in surgical technologies for lower limb orthopedics, announces its financial agenda... ► Artikel lesen | |
| 23.10.24 | Amplitude Surgical - Fiscal Year 2023-24: 106.0 M€ Sales and €27.1m EBITDA | 505 | Business Wire | Consolidated sales of €106.0 million, up 6.3% at constant exchange rates
EBITDA up to €27.1m (+3.7%), EBITDA rate at 25.6%.
Current operating income of €12.7 million
Cash... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BICO GROUP | 2,374 | -0,25 % | BICO Group AB: Publication of BICO Group AB Interim report January-June 2025 | A transformative quarter to secure long-term growth and profitability
Q2 2025 takeawaysBICO entered an agreement to divest MatTek and Visikol to Sartorius for USD 80m on cash and debt free basis, significantly... ► Artikel lesen | |
| PING AN HEALTHCARE | 1,732 | +1,64 % | Ping An Healthcare and Technology Company Limited: Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth | HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months ended June... ► Artikel lesen | |
| ORGANON | 8,100 | +0,77 % | Dividendenbekanntmachungen (15.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A10 NETWORKS INC US0021211018 0,06 USD 0,0514 EUR AGCO CORPORATION US0010841023 0,29 USD 0,2489 EUR ALBEMARLE CORPORATION PREF... ► Artikel lesen | |
| EMEIS | 14,190 | -0,42 % | emeis: Sales and Business Update at the End of June 20251 | Sustained growth in operating margins
Sustained revenue growth
+6.2% on a like-for-like basis
Net operational recovery
EBITDAR up nearly +20% on a like-for-like basis
EBITDA (excluding... ► Artikel lesen | |
| CYTOSORBENTS | 0,790 | +0,89 % | CytoSorbents Corporation: CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR | FDA appeal decision found no issues with DrugSorb-ATR device safety but upheld the De Novo denial, and proposes a potential path forward for market authorization... ► Artikel lesen | |
| CLARIANE | 4,698 | -0,34 % | Korian Stiftungsaward 2025 geht an vielfältig. GmbH Bremen - erster ambulanter Pflegedienst mit Fokus auf Sexualität und Vielfalt | München (ots) - Der diesjährige Korian Stiftungsaward für Vielfalt und Respekt in der Pflege der Korian Stiftung für Pflege und würdevolles Altern, geht an vielfältig. Bremen. Der ambulante Pflegedienst... ► Artikel lesen | |
| ARJO | 2,916 | -0,14 % | Arjo AB: Andréas Elgaard appointed new President and CEO of Arjo | Arjo's Board of Directors has appointed Andréas Elgaard new President and CEO of the Group. Andréas most recently comes from the position as President and CEO of the publicly listed ITAB Shop Concept... ► Artikel lesen | |
| M3 INC | 13,700 | +0,74 % | Deutliches Plus erfreut Inhaber der M3-Aktie (12,50 €) | Grund zur Freude haben Aktionäre von M3 : Das Papier steigt deutlich. Zu den stärksten Werten des Tages gehört heute der Anteilsschein von M3 mit einem Wertanstieg von 11,61 Prozent. Für das Papier... ► Artikel lesen | |
| DYNAVOX GROUP | 10,960 | +0,83 % | Dynavox Group AB: Dynavox Group Interim Report second quarter 2025 | Dynavox Group AB (publ) today announced its results for the second quarter 2025.
Comment from the Dynavox Group CEO Fredrik Ruben:
Dynavox Group delivered another quarter of exceptional growth and... ► Artikel lesen | |
| NYXOAH | 5,390 | -6,59 % | EQS-News: Nyxoah SA.: Nyxoah gibt Finanzergebnisse und operatives Update für das zweite Quartal bekannt | EQS-News: Nyxoah SA.
/ Schlagwort(e): Quartalsergebnis
Nyxoah gibt Finanzergebnisse und operatives Update für das zweite Quartal bekannt
18.08.2025 / 22:10 CET/CEST
Für... ► Artikel lesen | |
| INTERPACE BIOSCIENCES | 0,915 | +12,27 % | Interpace Biosciences, Inc.: Effective May 2, 2025, Interpace Diagnostics Will No Longer Accept Specimens for PancraGEN, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk | Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace"... ► Artikel lesen | |
| CHINA MEDICAL SYSTEM | 1,440 | -4,64 % | China Medical System Holdings Ltd.: CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers | SHENZHEN, CHINA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On 18 August, China Medical System Holdings Limited ("CMS" or the "Company") announced its interim results for the six months ended 30 June 2025... ► Artikel lesen | |
| NANOSONICS | 2,200 | 0,00 % | NANOSONICS LIMITED: FY25 Full Year Results webinar notification | ||
| VIVANI MEDICAL | 1,070 | +1,90 % | Vivani closes $10M financing, advances GLP-1 implant | ||
| NIAGEN BIOSCIENCE | 8,350 | +1,21 % | Niagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London Conference | Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces... ► Artikel lesen |
Das Unternehmen AMPLITUDE SURGICAL kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 6,100 Euro und damit -0,81 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AMPLITUDE SURGICAL finden Sie auf Wallstreet Online.